Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 3
1997 2
1999 7
2000 11
2001 11
2002 6
2003 13
2004 14
2005 19
2006 22
2007 21
2008 26
2009 23
2010 26
2011 40
2012 52
2013 67
2014 45
2015 44
2016 44
2017 39
2018 51
2019 32
2020 45
2021 42
2022 38
2023 34
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

701 results

Results by year

Filters applied: . Clear all
Page 1
Retigabine.
Porter RJ, Nohria V, Rundfeldt C. Porter RJ, et al. Neurotherapeutics. 2007 Jan;4(1):149-54. doi: 10.1016/j.nurt.2006.11.012. Neurotherapeutics. 2007. PMID: 17199031 Free PMC article. Review.
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. ...Adverse effects have been largely CNS-related and mild; most have occurred during the titration periods in the various studies. At …
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epi …
Identifying the mechanism of action of the Kv7 channel opener, retigabine in the treatment of epilepsy.
Zahra A, Liu R, Wang J, Wu J. Zahra A, et al. Neurol Sci. 2023 Nov;44(11):3819-3825. doi: 10.1007/s10072-023-06955-x. Epub 2023 Jul 13. Neurol Sci. 2023. PMID: 37442907 Review.
Thus, as a positive allosteric modulator (or opener) of KCNQ channels, retigabine has been the only clinically approved anti-seizure medication that acts on the KCNQ channels. ...Additional efforts are being made to emphasize the possible benefits and drawbacks of retig …
Thus, as a positive allosteric modulator (or opener) of KCNQ channels, retigabine has been the only clinically approved anti-seizure …
Clinical pharmacokinetics of retigabine/ezogabine.
Tompson DJ, Crean CS. Tompson DJ, et al. Curr Clin Pharmacol. 2013 Nov;8(4):319-31. doi: 10.2174/15748847113089990053. Curr Clin Pharmacol. 2013. PMID: 23342983 Review.
RESULTS: Retigabine is rapidly absorbed with a median time to C(max) of 0.5-2.0 hours. ...Systemic exposure to retigabine is unaffected by gender when normalized for body weight. ...
RESULTS: Retigabine is rapidly absorbed with a median time to C(max) of 0.5-2.0 hours. ...Systemic exposure to retigabine is u …
Retigabine for partial onset seizures.
Rheims S, Ryvlin P. Rheims S, et al. Expert Rev Neurother. 2012 May;12(5):509-17. doi: 10.1586/ern.12.33. Expert Rev Neurother. 2012. PMID: 22550979 Review.
Ezogabine/retigabine (RTG) is a novel antiepileptic compound that activates a voltage-sensitive neuronal-specific outward potassium current that decreases neuronal excitability. ...
Ezogabine/retigabine (RTG) is a novel antiepileptic compound that activates a voltage-sensitive neuronal-specific outward pota …
Retigabine: the newer potential antiepileptic drug.
Czuczwar P, Wojtak A, Cioczek-Czuczwar A, Parada-Turska J, Maciejewski R, Czuczwar SJ. Czuczwar P, et al. Pharmacol Rep. 2010 Mar-Apr;62(2):211-9. doi: 10.1016/s1734-1140(10)70260-7. Pharmacol Rep. 2010. PMID: 20508276 Free article. Review.
The metabolism of retigabine has nothing to do with cytochrome P450 enzymes and the drug undergoes glucuronidation and acetylation. ...The most prominent adverse effects due to retigabine combined with the existing antiepileptic treatment were dizziness, somnolence …
The metabolism of retigabine has nothing to do with cytochrome P450 enzymes and the drug undergoes glucuronidation and acetylation. . …
Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.
Deeks ED. Deeks ED. CNS Drugs. 2011 Oct 1;25(10):887-900. doi: 10.2165/11205950-000000000-00000. CNS Drugs. 2011. PMID: 21936589 Review.
Retigabine (ezogabine in the US) opens neuronal voltage-gated potassium channels, resulting in resting membrane potential stabilization, neuronal subthreshold excitability control and anticonvulsant effects. ...Retigabine was generally well tolerated in adult …
Retigabine (ezogabine in the US) opens neuronal voltage-gated potassium channels, resulting in resting membrane potential stab …
The interaction potential of retigabine (ezogabine) with other antiepileptic drugs.
Tompson DJ, Crean CS. Tompson DJ, et al. Curr Clin Pharmacol. 2014 May;9(2):148-56. doi: 10.2174/1574884708666131111192311. Curr Clin Pharmacol. 2014. PMID: 24219007 Review.
RESULTS: Retigabine is not a substrate for the major CYP enzymes and at clinically relevant concentrations there is little or no potential for retigabine to inhibit or induce the CYP enzymes or to inhibit the major renal drug transporters. ...Conversely, a populatio …
RESULTS: Retigabine is not a substrate for the major CYP enzymes and at clinically relevant concentrations there is little or no pote …
Retigabine: chemical synthesis to clinical application.
Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE. Blackburn-Munro G, et al. CNS Drug Rev. 2005 Spring;11(1):1-20. doi: 10.1111/j.1527-3458.2005.tb00033.x. CNS Drug Rev. 2005. PMID: 15867950 Free PMC article. Review.
These encouraging results suggest that retigabine may also prove useful in the treatment of other diseases associated with neuronal hyperexcitability. ...Early clinical studies have indicated that retigabine is rapidly absorbed and distributed, and is resistant to f …
These encouraging results suggest that retigabine may also prove useful in the treatment of other diseases associated with neuronal h …
Ezogabine (retigabine).
Stafstrom CE, Grippon S, Kirkpatrick P. Stafstrom CE, et al. Nat Rev Drug Discov. 2011 Sep 30;10(10):729-30. doi: 10.1038/nrd3561. Nat Rev Drug Discov. 2011. PMID: 21959281
Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. ...The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine …
Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. ...The …
Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity.
Musella S, Carotenuto L, Iraci N, Baroli G, Ciaglia T, Nappi P, Basilicata MG, Salviati E, Barrese V, Vestuto V, Pignataro G, Pepe G, Sommella E, Di Sarno V, Manfra M, Campiglia P, Gomez-Monterrey I, Bertamino A, Taglialatela M, Ostacolo C, Miceli F. Musella S, et al. J Med Chem. 2022 Aug 25;65(16):11340-11364. doi: 10.1021/acs.jmedchem.2c00911. Epub 2022 Aug 16. J Med Chem. 2022. PMID: 35972998 Free PMC article.
Neuronal Kv7 channels represent important pharmacological targets for hyperexcitability disorders including epilepsy. Retigabine is the prototype Kv7 activator clinically approved for seizure treatment; however, severe side effects associated with long-term use have led to …
Neuronal Kv7 channels represent important pharmacological targets for hyperexcitability disorders including epilepsy. Retigabine is t …
701 results